Literature DB >> 7451552

Effects of ribavirin on the development of the Friend leukemia.

U Opitz, H J Seidel, G Streissle.   

Abstract

Ribavirin (300 and 250 mg/kg i.p., respectively) had a toxic effect on hemopoietic stem cells in normal mice CFU-S, CFU-C, and especially CFU-E were reduced after a single treatment. The drug was further studied in mice infected with the polycythemia-inducing strain of the Friend virus (FV-P). In these mice a specific erythropoietin-independent CFU-E population (CFU-EI) replaces the normal erythropoiesis and can be considered a tumor cell population. With the in vitro technique for CFU-E, CFU-EI can easily be quantified and used as a sensitive marker for the development of the disease. Repeated doses of ribavirin reduced the increase of spleen weight after FV-P infection and the progressive transformation of normal CFU-E into CFU-EI was delayed. The further development of the disease remained unaltered. In vitro CFU-E and CFU-EI were inhibited at the same concentrations when the drug was added to the culture medium. In mice pretreated with multiple doses of hydroxyurea, ribavirin delayed the recurrence of Friend leukemia as seen from the spleen weight increase, but the CFU-E population was predominantly Ep-independent. It is concluded that the effects of the drug were due to its cytotoxicity rather than to a specific antiviral effect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7451552     DOI: 10.1007/bf00413175

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  Erythropoietin-independent erythroid colony formation in vitro by hemopoietic cells of mice infected with friend virus.

Authors:  S K Liao; A A Axelrad
Journal:  Int J Cancer       Date:  1975-03-15       Impact factor: 7.396

3.  Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A.

Authors:  N N Iscove; F Sieber; K H Winterhalter
Journal:  J Cell Physiol       Date:  1974-04       Impact factor: 6.384

4.  Erythroid stem cells in Friend-virus infected mice.

Authors:  U Opitz; H J Seidel; I Bertoncello
Journal:  J Cell Physiol       Date:  1978-07       Impact factor: 6.384

5.  Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-blind study during an outbreak of influenza.

Authors:  F Salido-Rengell; H Nasser-Quinones; B Briseno-Garcia
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

6.  Inhibition of influenza RNA synthesis by virazole (ribavirin).

Authors:  C Scholtissek
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

7.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

8.  Effect of ribavirin on murine cytomegalovirus infection.

Authors:  J N Dowling; B Postic; L O Guevarra
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

9.  Friend leukemia: rapid development of erythropoietin-independent hematopoietic precursors.

Authors:  J S Horoszewicz; S S Leong; W A Carter
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

10.  Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals.

Authors:  R W Sidwell; L B Allen; G P Khare; J H Huffman; J T Witkowski; L N Simon; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.